We present a case of presumed central anticholinergic syndrome due to a drug administration error. A 35-year-old woman was slow to emerge from anaesthesia for laparoscopic biliary surgery. Postoperative neurological and metabolic abnormalities were later diagnosed as central anticholinergic syndrome. Only after resolution of the clinical problems did the drug error origin of the syndrome become apparent. It was realized that hyoscine hydrobromide (scopolamine) had been inadvertently administered intraoperatively for biliary relaxation, instead of hyoscine butylbromide. This case report describes central anticholinergic syndrome and highlights potential problems involved for anaesthetists administering drugs they do not commonly use.
Hyoscine hydrobromide (scopolamine), a tertiary amine and acetylcholine antagonist, has been used since the nineteenth century as an antisialogogue, antiemetic and amnesic agent prior to anaesthesia 1 . Unlike glycopyrrolate, but similar to atropine, scopolamine crosses the blood brain barrier. It acts as a central nervous system (CNS) depressant and commonly causes drowsiness, hypnosis, amnesia and in some cases coma. In the elderly population it may cause agitation, delirium, excitement 1 and hyperpyrexia 2 . These signs and symptoms are known collectively as central anticholinergic syndrome 3 , and result from an absolute or relative reduction in cholinergic activity in the CNS 4 , possibley due to an antagonistic effect to arousal at a hypothalamic and brainstem level. Other side-effects due to peripheral antimuscarinic action include mydriasis, cycloplegia, tachycardia, bronchodilatation, dry mouth and urinary retention. These signs are not always seen if opposed by drugs such as neostigmine that act peripherally as a cholinesterase inhibitor. This is a report of central anticholinergic syndrome caused by a drug administration error and the in-advertent intravenous injection of hyoscine hydrobromide (scopolamine) instead of hyoscine butylbromide (Buscopan™).
CASE HISTORY
A 35-year-old woman, graded as ASA Physical Status 1, presented for a laparoscopic cholecystectomy because of retained gallstones. Her past medical and surgical history was unremarkable and she had no history of psychiatric illness. Her only medication was the oral contraceptive pill.
Prior to induction, an 18 gauge peripheral intravenous (IV) cannula was sited and 2.5 mg midazolam IV administered. Blood pressure was 120/80 mmHg and heart rate 72 beats per minute (bpm). General anaesthesia was induced with propofol 150 mg and fentanyl 100 µg and maintained with desflurane in oxygen and air. A size 4 Proseal Laryngeal Mask Airway (Laryngeal Mask Company, Henley-on-Thames, U.K.) was inserted and a nasogastric tube passed via the drain tube. Muscle relaxation was achieved using rocuronium 30 mg. The patient had no signs or symptoms of pyrexia preoperatively and her temperature intraoperatively was 36.3°C. Laparoscopic cholecystectomy was complicated by a retained gallstone in the distal common bile duct. During cholangiography, several attempts were made by the surgeon to flush out the stone using contrast medium. The surgeon requested glucagon 1.0 mg intravenously to induce biliary dilatation. The stone remained in the Anaesthesia and Intensive Care, Vol. 32, No. 3, June 2004 common bile duct and hyoscine butylbromide (Buscopan™, Boehringer Ingelheim Pty Ltd) was requested. As this drug is not usually found on the drug trolley, a nurse was asked to find the drug from central stores. Before administering the contents of the vials the drug label and drug dose was not checked properly by the anaesthetist. Consequently, the contents of two ampoules of hyoscine hydrobromide (scopolamine) were given inadvertently intravenously by the anaesthetist. A heart rate of 120 bpm was noted which lasted about 10 minutes before returning slowly to the baseline. The stone remained in the bile duct, and it was decided to abandon attempts to remove it during this procedure and attempt removal at endoscopic retrograde cholangiopancreatography the following day. During the course of the laparoscopic procedure a further dose of rocuronium 20 mg, fentanyl 100 µg, parecoxib 40 mg and tramadol 100 mg were given IV and local anaesthetic infiltrated around the port sites.
Muscle relaxation was reversed with neostigmine and glycopyrrolate and the train-of-four was noted as four without fade. Despite being fully reversed and making adequate respiratory excursion, the patient remained very hypotonic and unresponsive to voice or bilateral jaw thrust. The patient's pupils were widely dilated and her tongue was fasciculating. The blood pressure and heart rate were normal and she had a saturation of 99% on pulse oximetry. The Proseal LMA was removed and replaced with a facemask with oxygen at 6 l/min, and the patient transferred to the recovery area.
In the recovery room, the patient's blood pressure was 130/80 mmHg and pulse rate 85 bpm. A mild pyrexia of 37.6°C and a normal blood sugar level were noted. There was considerable concern because she was extremely drowsy, appeared very flushed and had only jerky limb movements and eye-opening to voice stimulation. Symmetrical chest movement was noted on auscultation, and vesicular breath sounds were heard equally throughout. An arterial blood gas analysis was carried out to exclude hypoxaemia and hypercapnia as a cause of her apparent drowsiness. This investigation showed a mixed respiratory and metabolic acidosis (pH 7.21), a raised P a CO 2 (50 mmHg), bicarbonate of 20 mmol/l and base deficit of 8 mmol/l. The P a O 2 was 194 mmHg on 6 l/min. An anion gap was not calculated. Manual intermittent positive pressure ventilation (IPPV) and continuous positive airway pressure (CPAP) with a Mapleson "C" Circuit were used to support ventilation as required. Blood was taken for serum urea and electrolyte concentration (sodium 138, potassium 4.0, chloride 106, urea 2.3, creatinine 56). Over the following few minutes the patient became more agitated and confused and required physical restraint. Small boluses of propofol were given to provide sedation. The patient appeared to be complaining of lower abdominal pain and on catheterization of her bladder, 600 ml of urine was drained. Fentanyl 50 µg was given for analgesia. After three hours in the recovery ward, the patient had recovered sufficiently to be taken to the High Dependency Unit for further observation and management of her symptoms. No diagnosis had been made to explain her acidaemia or neurological state. Her symptoms persisted for approximately 3.5 hours after which she had no memory of preceding events.
The following day, the patient had made a full recovery without any recall of the events of the day before. A review was made of the case and the patient's signs and symptoms. Upon looking at and comparing vials of Buscopan (hyoscine butylbromide) and scopolamine (hyoscine hydrobromide) it became clear that a drug error had occurred during the course of anaesthesia. Two vials of hyoscine hydrobromide (scopolamine, 2 x 400 µg) had been given instead of two ampoules of hyoscine butylbromide (Buscopan 2 x 20 mg). We believe this drug error resulted in a central anticholinergic syndrome. A critical incident form was filled in accordingly.
DISCUSSION
Many different drugs have been implicated in the pathogenesis of central anticholinergic syndrome. Implicated drugs used in anaesthesia include anticholinergic agents such as atropine 5 and scopolamine 6 , promethazine, benzodiazepines 7 , opioids 8 , inhalational volatile anaesthetics such as halothane and isoflurane 7 and also ketamine 9 . The incidence of central anticholinergic syndrome following routine anaesthesia has been reported as 1.9% by Link and co-workers 7 . This group also showed a significantly higher incidence in women. However, in their population of 962, 87% of patients received atropine perioperatively and 78% received pethidine and promethazine as premedication (the gender distribution of premedication is not reported). Holzgrafe and colleagues found the incidence of central anticholinergic syndrome in 1727 patients premedicated with hyoscine to be 11.2% 10 . Cook and Spence commented that, given the diverse symptoms attributed to this syndrome, a rigid definition and hence true incidence of the syndrome is hard to quantify 3 . Certainly, in the U.K. where the use of anticholinergic premedication is declining, the incidence of central anticholinergic syndrome is likely to be much less than those quoted.
The diagnosis of central anticholinergic syndrome should be one of exclusion. Common respiratory and metabolic causes of delayed awakening should be ruled out. Specifically, incomplete reversal of muscle relaxation, delayed recovery from residual volatile agents and excessive opioid levels, alterations in electrolyte and acid-base balance, hypothermia, hypoglycaemia and intraoperative neurological damage should be excluded. Central anticholinergic syndrome can be diagnosed and treated with the cholinesterase inhibitor physostigmine. Physostigmine is a tertiary amine that freely crosses the blood brain barrier. Resolution of presenting symptoms after the administration of 0.03 to 0.04 mg.kg -1 of physostimine is diagnostic of the syndrome. Physostigmine has an onset time of 3 to 15 minutes and duration of approximately 120 minutes. In some cases repeated doses of physostigmine and even infusions have been required 11 . Side-effects of physostigmine include nausea and vomiting, bradycardia, hypertension, seizures and bronchoconstriction. It should be given intravenously over a few minutes with ECG monitoring in place and caution should be used in patients with asthma, epilepsy and Parkinson's disease.
Although central anticholinergic syndrome is a diagnosis of exclusion and difficult to define, we feel that after an inadvertent injection of 800 µg of scopolamine and signs highly suggestive of reduced cholinergic activity in the CNS (drowsiness followed by agitation, mydriasis, urinary retention), central anticholinergic syndrome is the most likely diagnosis. The presence of pyrexia and respiratory acidosis further supports the diagnosis 2,12,13 . A differential diagnosis may include agitation related to pain -a picture complicated by excessive sedation due to scopolamine. As physostigmine was not used to provide a definitive diagnosis, our diagnosis can be considered unconfirmed.
CONCLUSIONS
The reduction in the use of anticholinergic premedication and the increased use of glycopyrrolate, which does not cross the blood brain barrier and therefore is unlikely to cause central effects, should lead to a low incidence of central anticholinergic syndrome. Commonly used anaesthetic drugs not usually considered to have significant central anticholinergic action, such as fentanyl, pethidine and even possibly large doses of propofol 14 , may contribute to central anticholinergic syndrome. Anaesthetists should consider this syndrome in any patient displaying a delay in awakening after anaesthesia when other common metabolic and respiratory conditions have been excluded. The syndrome should particularly be considered when classic peripheral signs of anticholinergic action, such as mydriasis, tachycardia and urinary retention, occur in conjunction with the central neurological signs. As in our case, a history of administration of an anticholinergic agent which crosses the blood brain barrier, such as scopolamine, especially in large dose, makes the occurrence of central anticholinergic syndrome more likely. In suspected cases, administration of physostigmine can be both diagnostic and therapeutic.
This case highlights the importance of vigilantly checking drugs, especially when those drugs are not commonly used in anaesthetic practice. The fact that "hyoscine" was administered but the distinction between "hyoscine butylbromide" and "hyoscine hydrobromide" was missed underlines the importance of checking the complete drug description.
